Botulinum toxins in neurological disease
- PMID: 15116366
- DOI: 10.1002/mus.20033
Botulinum toxins in neurological disease
Abstract
Botulinum toxins are among the most potent neurotoxins known to humans. In the past 25 years, botulinum toxin has emerged as both a potential weapon of bioterrorism and as a powerful therapeutic agent, with growing applications in neurological and non-neurological disease. Botulinum toxin is unique in its ability to target peripheral cholinergic neurons, preventing the release of acetylcholine through the enzymatic cleavage of proteins involved in membrane fusion, without prominent central nervous system effects. There are seven serotypes of the toxin, each with a specific activity at the molecular level. Currently, serotypes A (in two preparations) and B are available for clinical use, and have been shown to be safe and effective for the treatment of dystonia, spasticity, and other disorders in which muscle overactivity gives rise to symptoms. This review focuses on the pharmacology, electrophysiology, immunology, and application of botulinum toxin in selected neurological disorders.
Similar articles
-
Botulinum toxins: pharmacology and its current therapeutic evidence for use.Neurol India. 2003 Dec;51(4):455-60. Neurol India. 2003. PMID: 14742921 Review.
-
Botulinum toxin: a dreaded toxin for use in human being.J Indian Med Assoc. 2002 Oct;100(10):607-8, 610-2, 614. J Indian Med Assoc. 2002. PMID: 12452515 Review.
-
[Botulinum toxin: structure, mode of action and therapeutic use].Postepy Hig Med Dosw. 1994;48(5):505-20. Postepy Hig Med Dosw. 1994. PMID: 7638099 Review. Polish.
-
The current use of botulinum toxin.J Clin Neurosci. 2000 Sep;7(5):389-94. doi: 10.1054/jocn.2000.0684. J Clin Neurosci. 2000. PMID: 10942658 Review.
-
Botulinum toxin: from poison to remedy.Neurotoxicology. 1997;18(3):761-70. Neurotoxicology. 1997. PMID: 9339823 Review.
Cited by
-
A Pilot Study of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Subtype A2 for Post-Stroke Lower Limb Spasticity: Comparison with OnabotulinumtoxinA.Toxins (Basel). 2022 Oct 28;14(11):739. doi: 10.3390/toxins14110739. Toxins (Basel). 2022. PMID: 36355989 Free PMC article.
-
Clinical Safety and Tolerability of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Botulinum Neurotoxin Subtype A2, in Comparison with Subtype A1 Toxins.Toxins (Basel). 2021 Nov 22;13(11):824. doi: 10.3390/toxins13110824. Toxins (Basel). 2021. PMID: 34822610 Free PMC article.
-
Contribution of Single-Fiber Evaluation on Monitoring Outcomes Following Injection of Botulinum Toxin-A: A Narrative Review of the Literature.Toxins (Basel). 2021 May 17;13(5):356. doi: 10.3390/toxins13050356. Toxins (Basel). 2021. PMID: 34067540 Free PMC article. Review.
-
The Efficacy of Dose Increments of Botulinum Toxin A in the Treatment of Childhood Esotropia.Clin Ophthalmol. 2021 Jan 12;15:113-120. doi: 10.2147/OPTH.S294396. eCollection 2021. Clin Ophthalmol. 2021. PMID: 33469257 Free PMC article.
-
Jitter Evaluation in Distant and Adjacent Muscles after Botulinum Neurotoxin Type A Injection in 78 Cases.Toxins (Basel). 2020 Aug 27;12(9):549. doi: 10.3390/toxins12090549. Toxins (Basel). 2020. PMID: 32867187 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
